Pular para o conteúdo principal
Ranking Invest

IMCR - Immunocore Holdings plc

Segmento: HealthcareImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Análise Ranking Invest

Valuation estimado
-13,23%
$ 328.26 Mi
Valor de Mercado
$ 1.67 Bi
Sobrepreço (AV)+409.7%
IVR
0.20A companhia vale 0,20 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.08O valuation alternativo equivale a -8% do valor de mercado da companhia.
MLL
-0.08O lucro líquido dos controladores em 16 trimestres equivale a -8% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 419.80 Mi

Dívida Líquida

-$ 484.92 Mi

L4T

-$ 18.07 Mi

MM4T

-4.37%

Indicadores Básicos

ROE

-4.31%

Índices de Previsibilidade

Receita Líquida

C0.07

Lucro

E1.42

Margem

E1.45

Índices de Tendência

Receita Líquida

A10.82

Lucro

C3.11

Margem

B4.30

Índices de Endividamento

DIV/PAT

-1.16

DIV/L4T

26.83

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.